Engineered Therapeutic Antibody Against SARS-CoV-2
Issued Date
2023-01-01
Resource Type
eISSN
21965471
Scopus ID
2-s2.0-85176471980
Journal Title
Current Clinical Microbiology Reports
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Clinical Microbiology Reports (2023)
Suggested Citation
Chulanetra M. Engineered Therapeutic Antibody Against SARS-CoV-2. Current Clinical Microbiology Reports (2023). doi:10.1007/s40588-023-00212-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/91113
Title
Engineered Therapeutic Antibody Against SARS-CoV-2
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Purpose of Review: The success and failure of therapeutic antibodies against SARS-CoV-2 offer a lesson on therapeutic antibody design and development. Recent Findings: Therapeutic antibody against SARS-CoV-2 facing challenging antibody escape mutation. A paratope design strategy targeting pancoronavirus conserved epitope(s) and combining two antibodies as antibody cocktails or bispecific antibodies may overcome antibody escape mutations of the SARS-CoV-2 spike. Instead of designing broadly neutralizing antibodies, repurposing antibodies can target viral or host molecules to inhibit the virus and alleviate dysregulation of the host immune response. Summary: Detailed strategies for engineering therapeutic antibodies, including antibody format, are reviewed in this article.